There are currently 66 clinical trials in Arlington, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Clinical Research Institute, Texas Retina Associates, GSK Investigational Site and Texas Clinical Research Institute, Llc. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
NCT05832931
Recruiting
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2024
Locations: Site Number: USA037-1, Arlington, Texas
Conditions: Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Register for Updates
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232
Recruiting
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).
Gender:
All
Ages:
Between 16 years and 80 years
Trial Updated:
04/02/2024
Locations: Cross Timbers Surgery Center(Proctosigmoidoscopy), Arlington, Texas +4 locations
Conditions: Ulcerative Colitis
Register for Updates
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835
Recruiting
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Z... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Liberty Research Center, Arlington, Texas +1 locations
Conditions: Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
NCT05832151
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants wil... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: North Hills Medical Research Inc. (North Hills Familiy Medicine), Arlington, Texas
Conditions: Diabetic Gastroparesis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)
NCT04123795
Recruiting
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/28/2024
Locations: Ps0007 50156, Arlington, Texas
Conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
Register for Updates
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842
Recruiting
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC). Participants will also have inadequate response or intolerance to ursodeoxycholic acid (UDCA) a drug used to treat PBC. PBC is a disease that progresses slowly. It causes damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many people with PBC may re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Texas Clinical Research Institute, Arlington, Texas
Conditions: Primary Biliary Cholangitis (PBC)
Register for Updates
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
NCT04757610
Recruiting
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/26/2024
Locations: ShORe Investigational Site, Arlington, Texas
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: The Center for Cancer and Blood Disorders - Magnolia,515 W. Mayfield Rd., Arlington, Texas
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Register for Updates
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115
Recruiting
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/26/2024
Locations: Arlington Research Center, Inc., Arlington, Texas
Conditions: Plaque Psoriasis
Register for Updates
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Texas Clinical Research Institute, Arlington, Texas
Conditions: NASH, Cirrhosis, Liver
Register for Updates
The Acute Effect of and Energy Drink vs. Water Consumption on MAP, HR, and Energy Metabolism
NCT06330649
Recruiting
The objective of this protocol is to investigate the effect of consumption of a commercially available energy drink beverage on blood pressure, heart rate, and energy metabolism
Gender:
All
Ages:
Between 18 years and 30 years
Trial Updated:
03/18/2024
Locations: UT Arlington - Science and Engineering Innovation and Research Building, Arlington, Texas
Conditions: Cardiovascular Diseases, Hypertension, Diet
Register for Updates
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
NCT05514535
Recruiting
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home vi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Arlington Family Res. Ctr Inc, Arlington, Texas
Conditions: Diabetes Mellitus, Type 2, Obesity
Register for Updates